Merck to lower prices for some drugs

Merck to lower prices for some drugs
© Thinkstock

The pharmaceutical company Merck on Thursday announced it would lower the costs of some drugs in its portfolio.

The company will drop the price of Zepatier, a Hepatitis C drug, by 60 percent, and decrease the costs of "several other" drugs by 10 percent. 

It also said it would not increase the average net price of drugs in its portfolio by more than inflation annually. 

ADVERTISEMENT

The news was met with praise by the Trump administration, which took credit for the decreases by citing the president's tough talk on drug prices. 

“The President’s blueprint for lower drug prices is working, drug prices are coming down, and American patients are going to see the savings in their pocketbook. We welcome Merck’s decision to reduce prices and restrain future price hikes," Health and Human Services Secretary Alex Azar said in a statement. 

“This decision is a response to President TrumpDonald John TrumpTrump directed Cohen to lie to Congress about plans to build Trump Tower in Moscow during 2016 campaign: report DC train system losing 0k per day during government shutdown Senate Republicans eye rules change to speed Trump nominees MORE’s blueprint and reflects the industry’s understanding that the President is serious about bringing change to our drug markets." 

Merck is the first drug company to announce price decreases since the administration released its blueprint, though two other companies — Pfizer and Novartis — have said it would not increase the prices of drugs for the rest of 2018.

Drug pricing experts, however, note that Zepatier is not a key part of Merck’s business and hasn’t been as profitable as other drugs in its portfolio.

The company has not released a list of other drugs that will get price decreases.